National Institute for Medical Research, Tanzania   Report issue

Government Phase 1 Phase 2 Phase 3 Phase 4
Founded: Salaam Tanzania, United Republic of (1979)

Organization Overview

First Clinical Trial
2004
NCT00146731
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

National Institute for Medical Research in Tanzania | National Institute for Medical Research, Tanga, Tanzania | National Institute for Medical Research, Tanzania | National Institute of Medical Research, Tanzania | NIMR Mwanza

Active Ingredients

Drugs in Phase 4 Trials (10)

amodiaquine (camoquin) (4 trials)

artesunate (6 trials)

azithromycin (zithromax) (2 trials)

coartem (4 trials)

dihydroartemisinin (7 trials)

human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant (Gardasil) (1 trial)

lumefantrine (Coartem) (4 trials)

piperaquine (7 trials)

pyrimethamine (daraprim) (5 trials)

sulfadoxine (5 trials)

Drugs in Phase 3 Trials (23)

abamectin (1 trial)

acetylcysteine (mucomyst) (2 trials)

bedaquiline (sirturo) (1 trial)

chlorproguanil (3 trials)

cisplatin (platinol) (1 trial)

dapsone (aczone) (3 trials)

ethambutol (myambutol) (1 trial)

etofenprox (1 trial)

fenperoximate (1 trial)

gimeracil (1 trial)

isoniazid (nydrazid) (2 trials)

lactobacillus reuteri (1 trial)

lactobacillus rhamnosus (3 trials)

mefloquine (lariam) (2 trials)

metronidazole (flagyl) (1 trial)

oteracil (1 trial)

pretomanid (1 trial)

pyrazinamide (Aldinamide) (1 trial)

rifampin (1 trial)

rifapentine (priftin) (1 trial)

s-1 (1 trial)

sutezolid (1 trial)

tegafur (1 trial)

Drugs in Phase 2 Trials (14)

dna-hiv-pt123 (1 trial)

efavirenz (sustiva) (1 trial)

emtricitabine (emtriva) (1 trial)

fozivudine tidoxil (1 trial)

h56 (1 trial)

hiv glycoprotein cn54gp140 vaccine (1 trial)

hivis dna vaccine (1 trial)

ic31 (1 trial)

lamivudine (epivir) (1 trial)

maytenus senegalensis (1 trial)

mva-cmdr (1 trial)

tenofovir (viread) (1 trial)

tenofovir alafenamide (genvoya) (1 trial)

zidovudine (retrovir) (1 trial)

Drugs in Phase 1 Trials (4)

hepatitis b vaccine (recombinant) (Recombivax) (1 trial)

msp3 (1 trial)

msp 3 long synthetic peptide (1 trial)

msp3 vaccine (1 trial)

Drugs in Other Trials (8)

albendazole (Albenza) (1 trial)

chlorfenapyr (1 trial)

cow milk (1 trial)

moringa (1 trial)

piperonyl butoxide (Rid Mousse) (1 trial)

praziquantel (biltricide) (1 trial)

pyriproxyfen (1 trial)

sorghum (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cardiotoxicity (Phase 2)

Diarrhea (Phase 3)

HIV Infections (Phase 2)

Infections (Phase 2)

Latent Tuberculosis (Phase 2)

Malaria (Phase 4)

Malaria, Falciparum (Phase 4)

Parasitemia (Phase 2)

Tuberculosis (Phase 2)

Tuberculosis, Pulmonary (Phase 2)

Uterine Cervical Neoplasms (Phase 4)

Vaginal Diseases (Phase 3)

Vaginosis, Bacterial (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 32
  • # of Trial APIs: 59